NDYNinactive

COEPTIS THERAPEUTICS INC.

Biopharma developer (SEC filing verified)·Pre-clinical

OncologyNeurologyImmunology

What we can confirm

BioSniper Score:: 3.3 / 10
Lead Asset:: cd38-gear-nk (Preclinical)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 3.3 / 10 · Lead Asset: cd38-gear-nk (Preclinical)

BioSniper AIPage evidence connected

Prepared research question

What matters most for NDYN—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

3.3/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

cd38-gear-nk (Preclinical)

Next Catalyst

—

Tracking 2 pipeline candidates for COEPTIS THERAPEUTICS INC..

Run COEPTIS THERAPEUTICS INC. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

Turn available COEPTIS THERAPEUTICS INC. facts into screen rules or deeper checks
Show cited findings, blockers, and unresolved evidence together
Save the logic and rerun it as the company evidence changes

Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Frequently asked questions

What is COEPTIS THERAPEUTICS INC.'s lead drug candidate?

COEPTIS THERAPEUTICS INC.'s most advanced tracked candidate is cd38-gear-nk (Preclinical) for CD38-related cancers (e.g., multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia).

What therapeutic areas does COEPTIS THERAPEUTICS INC. focus on?

COEPTIS THERAPEUTICS INC. develops therapies across Oncology, Neurology, Immunology.

923 companies304,841 SEC filings22,642 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.